Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage

Thrombosis Journal

Table 2 Summary of rFVIIa treated other bleeding patients (OBP) who survived >4 hours

P#	Age Sex	Procedure	Co-morbidities	Response to rFVIIa								Outcome
				Pre rFVIIa				Post rFVIIa
				R	P	F	C	R	P	F	C
2*	48F	Colectomy	Colon cancer	4	6	24	70	2	0	2	0	Died
15*	26F	Cystectomy, nephrectomy, pelvic fracture, termination of Pregnancy	MVA, 20 weeks gestation	18	12	8	0	6	6	10	0	Survived
16	53M	Left femur fixation	Multiple myeloma	12	12	6	0	0	0	0	0	Survived
19	82M	Shoulder replacement	HTN, CAD, Renal failure	7	10	20	10	2	6	4	0	Survived
21	54F	Liver laceration	Trauma	23	17	34	20	3	6	10	0	Survived
22	24M	Neck soft tissue trauma	FVII deficiency	2	0	4	0	0	0	0	0	Survived
23	64F	Liver laceration	Dialysis	28	36	33	0	0	0	0	0	Died
28	30F	Postpartum hemorrhage	None	12	18	6	10	0	0	0	0	Survived
29	64M	Gastrointestinal bleed	FVIII inhibitor	2	0	0	0	0	0	0	0	Survived
38	60M	Thyroidectomy	VWF deficiency	4	12	12	4	0	0	0	0	Survived
40	40F	Splenic subcapsular bleed	Amyloidosis, coumadin overdose	4	0	8	0	0	0	0	0	Survived
Average				10	11	14	10	1	2	2	0
P value								.004	.017	.017	.122

P: Patient
R: Red Blood Cell;
P: Platelet; F: Fresh Frozen Plasma; C: Cryoprecipitate
M: Male; F: Female
EF: Left Ventricular Ejection Fraction
VWF: von Willebrand Factor
* Patient continued to require blood transfusion past 24 hours post rFVIIa treatment.

ISSN: 1477-9560